Volv Global

Platinum Sponsor

Volv Global is the leader in optimising healthcare with data-driven, AI-powered disease insights for rare and difficult-to-diagnose diseases.

Our mission is to personalise healthcare for patients, accelerate scientific discovery, de-risk the development of innovative therapies and reduce the cost of healthcare. We do this by enabling earlier and faster diagnosis to close the gap between diagnosis and treatment and, ultimately, improve outcomes for those living with rare diseases.

Volv Global SA is a leading data science company that personalises and optimises healthcare for rare and difficult-to-diagnose diseases by enabling precise, data-driven, AI-powered disease insights for better patient management. In contrast to traditional methods, we help clinicians to recognise undiagnosed patients, detect them earlier, and differentiate the fast progressors with urgent needs. This improves outcomes for people living with disease by speeding up therapeutic development, reducing the cost of healthcare, and helping close the diagnostic gap, while also delivering increased value to healthcare providers and payers. 

Volv Global applies innovative and proprietary machine learning methodologies to population-scale data such as electronic health and claims records. This generates unique and powerful insights, which can enrich disease understanding and support the detection and triage of people living with undiagnosed rare and difficult-to-diagnose diseases.

Volv Global’s inTrigue technology engine uses machine learning to learn digital biomarkers for any human disease, with a particular focus on difficult-to-diagnose conditions, where there is significant unmet need. This transforms disease management and treatment at the individual patient level, allowing a paradigm shift in targeting accuracy. inTrigue innovates clinical practice by enabling significantly earlier patient diagnosis by clinical professionals, thereby relieving patients, caregivers, healthcare providers and payers of emotional, time and cost burdens.

Innovators in the development of new therapies for difficult-to-diagnose diseases benefit from being able to establish better clinical development strategies much earlier in the development lifecycle, improving planning robustness and efficiency. Healthcare providers and payers benefit from better understanding of disease progression, outcomes and endpoints.

Volv Global does not hold patient data, by design, relying on trustworthy data processors in different geographies. The company’s solutions overcome common real-world data shortcomings that standard machine learning approaches cannot manage well. Uniquely, Volv’s solutions overcome data bias, are universally adaptable, agnostic to disease, treatment, healthcare system and clinical coding.

Volv Global has an international presence, with a multinational team across Europe and the USA.

www.volv.global

website